Data as of Jan 23
| +2.59 / +1.66%|
The 20 analysts offering 12-month price forecasts for Pharmacyclics Inc have a median target of 159.00, with a high estimate of 253.00 and a low estimate of 128.00. The median estimate represents a +0.28% increase from the last price of 158.55.
The current consensus among 22 polled investment analysts is to Buy stock in Pharmacyclics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.